Thomas Schluep Chief Scientific Officer, Insert Therapeutics

Thomas Schluep, Sc.D. is the Chief Scientific Officer at Insert Therapeutics, a privately held biopharmaceutical company. He is responsible for Insert’s drug discovery and development programs. Insert is using its proprietary polymeric transport system, Cyclosert™, to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert’s lead drug candidate, a combination of its linear, cylodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006.

Prior to joining Insert in 2004, Dr. Schluep was in charge of the non-viral gene therapy program at Canji, Inc., a wholly owned subsidiary of Schering-Plough. While at Canji, he held multiple positions of increasing responsibility in the development, manufacture, and analytical testing of non-viral and adenoviral gene therapy vectors. A constant interest of Dr. Schluep has been to understand the role nanotechnology can play in enhancing the efficacy and therapeutic index of a wide variety of therapeutics. He holds a Sc.D. in Process Engineering and an MS in Biotechnology, both from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Speaking in the Nanotech for Investors Summit.

Back to Conferences & Symposia